Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation
Bortezomib-melphalan-prednisone combination is one of the standards of care for nontransplant eligible patients with newly diagnosed multiple myeloma. However, bortezomib intravenous (twice weekly for 4 cycles then weekly for 5 cycles) results in ~13% of patients with grade 3-4 peripheral neuropathy. Bortezomib subcutaneous (SQ) and weekly delivery, improves tolerability without impairment of efficacy. The aim of this study was to evaluate the safety and effectiveness of SQ bortezomib-based combinations in nontransplant eligible patients with newly diagnosed myeloma in a real-world setting.
Source: Seminars in Hematology - Category: Hematology Authors: Felipe de Arriba de la Fuente, Maria Soledad Dur án, Miguel Ángel Álvarez, Isabel López Sanromán, Ana Maria Dios, Rafael Ríos Tamayo, Ricarda García, Marta Sonia González, Elena Prieto, Abelardo Bárez, Fernando Escalante, Aurelia Tejedor, Mónica Tags: Review Source Type: research
More News: Brain | Hematology | Myeloma | Neurology | Peripheral Neuropathy | Prednisone | Study | Velcade